Sanofi SA (ADR) (NYSE:SNY) is the world’s No. 5 pharmaceutical company. It has over 100 manufacturing sites in 41 countries and has 110,000 employees in 100 countries. Its five top divisions do $40 billion in sales every year, and it …
Value investing is easily one of the most popular ways to find great stocks in any market environment. After all, who wouldn’t want to find stocks that are either flying under the radar and are compelling buys, or offer up tantalizing …
At this point, bad news is coming in consistently to the point that any significant piece of good news could catapult the stock higher, making Sanofi an interesting choice for dip-buyers. The latest setback the company has had stems from …
Shares of Sanofi slid last week following news of the company’s bid for takeover of another pharmaceutical company, with shares falling 7 percent to a Friday close of $40.98 per share. Sanofi announced a bid for Medivation, even after the …
"Consequently the company has reduced prices of such products. This will have an adverse impact on the sales and profitability of the company," it added. Sanofi India stock was trading at Rs 4,380, up 1.36 per cent, on BSE.
Sanofi SA (ADR) (NYSE:SNY) the $130 billion French drug manufacturer, is trying desperately to maintain its position as a leader in diabetes drugs. Its newest insulin product, Toujeo, just got approved by regulators for sale in the U.S., and …